OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Freedom Finance and Binance Join Forces in Digital Assets 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Bank of America Merrill Lynch 2018 Health Care Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on May 17, 2018, at 10:40 a.m. P.T./ 1:40 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Christopher Keenan
VP, Investor Relations and Corporate Communications
[email protected]
650-383-0823
